Higher quality data, proven results
A recent independent study comparing 9 scRNA-seq technologies found that, “overall, 10x FRP [Next GEM Flex] exhibited the highest ranked analytical performance followed by 10x 3' [Next GEM Universal 3'].” (1)
Source: Reprinted from De Simone et al., 2025, under Creative Commons License
Performance improvements for GEM-X Universal 3' (2024) versus Next GEM Universal 3' (2018).
Explore data from the Fred Hutch Innovation Lab demonstrating the performance advancements for Chromium GEM-X assays over previous Next GEM technology.
Achieve up to 80% cell recovery efficiency for a wide array of cell types and samples, including FFPE, with GEM-X technology.
Source: Reprinted from De Simone et al., 2025, under Creative Commons License
- Identify rare cell types and detect rare transcripts
- Improved detection of fragile cell types, including neutrophils
- Achieve quality insights from precious samples and small cell volume
- Recover up to 60% more of your sample compared to manual pipetting methods
Source: Reprinted from De Simone et al., 2025, under Creative Commons License
Source: Aggregated from Supplementary Table 4b from De Simone et al., 2025, under Creative Commons License
Perform small- to large-scale projects quickly and seamlessly, processing 1-128 samples or up to 2.56 million cells per run.
Cell suspensions
Fresh tissue
Frozen tissue
FFPE tissue
Gene expression
TCR & BCR sequencing
Cell surface protein
CRISPR screening
Chromatin accessibility
Reduce errors and achieve high-quality data with exceptional reproducibility across experiments, users, and chips with our Chromium X instrument family—including a low-cost option to get you started.
- Ensures consistent performance across experiments, users, and chips.
- Minimizes handling and user errors with fast and reliable workflows.
- Makes the most of your precious samples with cell recovery rates of up to 80%.
- Gives higher return on your sequencing budget by letting you reduce reads by up to 50%.
- Introduces variability across users and assays with manual protocols.
- Relies on long workflows with labor-intensive, error-prone methods.
- Misses critical data from important cell populations with low cell recovery rates.
- Increases sequencing costs since lower sensitivity requires more reads.